Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Peptide containing doai
Reexamination Certificate
2004-05-07
2008-08-26
Naff, David M. (Department: 1657)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Peptide containing doai
C424S484000, C424S485000, C424S486000, C424S487000, C424S488000, C424S094600, C424S094610, C435S177000, C435S178000, C435S180000, C435S181000, C436S528000, C436S532000, C530S408000, C530S812000, C530S816000
Reexamination Certificate
active
07417021
ABSTRACT:
A biologically active conjugate is disclosed comprising a biopolymer and a therapeutic agent joined by a disulfide bond. The conjugate, when formulated in a pharmaceutical composition with a suitable carrier, has improved in vivo stability and activity, and can be targeted to a variety of cells, tissues and organs.
REFERENCES:
patent: 4582865 (1986-04-01), Balazs et al.
patent: 4636524 (1987-01-01), Balazs et al.
patent: 4937270 (1990-06-01), Hamilton et al.
patent: 5017229 (1991-05-01), Burns et al.
patent: 5157123 (1992-10-01), Zara et al.
patent: 5169934 (1992-12-01), Clark et al.
patent: 5354853 (1994-10-01), Staveski et al.
patent: 5362478 (1994-11-01), Desai et al.
patent: 5439686 (1995-08-01), Desai et al.
patent: 5451661 (1995-09-01), Wan et al.
patent: 5496872 (1996-03-01), Constancis et al.
patent: 5498421 (1996-03-01), Grinstaff et al.
patent: 5527893 (1996-06-01), Burns et al.
patent: 5560933 (1996-10-01), Soon-Shiong et al.
patent: 5585361 (1996-12-01), Burns et al.
patent: 5635207 (1997-06-01), Grinstaff et al.
patent: 5639473 (1997-06-01), Grinstaff et al.
patent: 5760200 (1998-06-01), Miller et al.
patent: 5760220 (1998-06-01), Giguere et al.
patent: 5855987 (1999-01-01), Margel et al.
patent: 5874417 (1999-02-01), Prestwich et al.
patent: 5902795 (1999-05-01), Toole et al.
patent: 5932552 (1999-08-01), Blanchard et al.
patent: 6030958 (2000-02-01), Burns et al.
patent: 6174999 (2001-01-01), Miller et al.
patent: 6235726 (2001-05-01), Burns et al.
patent: WO 91/14696 (1991-10-01), None
patent: WO 93/08842 (1993-05-01), None
patent: WO 98/52614 (1998-11-01), None
patent: WO 99/26595 (1999-06-01), None
patent: WO 99/66063 (1999-12-01), None
Danishefsky et al., Conversion of Carboxyl Groups of Mucopolysaccharides Into Amides of Amino Acid Esters,Carbohydrate Research, vol. 16, pp. 199-205 (1971).
Sparer et al., Controlled Release from Glycosaminoglycan Drug Complexes, Controlled Release Delivery Systems, Chapter 6, pp. 107-119 (1983).
Raja et al., Preparation of Alkylamine and125I-Radiolabeled Derivatives of Hyaluronic Acid Uniquely Modified at the Reducing End, Analytical Biochemistry, vol. 139, pp. 168-177 (1984).
Wu, et al., Receptor-mediated in Vitro, Gene Transformation by a Soluble DNA Carrier System, theJournal of Biological Chemistry, vol. 262, No. 10, pp. 4429-4432 (1987).
Dadley-Moore, D. L., Synthetic peptide antigens induce antibodies toTaenia ovisoncospheres,Vaccine, vol. 17, pp. 1506-1515 (1999).
Bernkop-Schnurch et al., Development of controlled drug release systems based on thiolated polymers, J. Controlled Release, vol. 66, pp. 39-48 (2000).
Pouyani et al., “Functionalized Derivatives of Hyaluronic Acid Oligosaccharides: Drug Carriers and Novel Biomaterials”,Advance ACS Abstracts, pp. 339-347, May 1, 1994.
Mason et al., “Attachment of hyaluronic acid to polypropylene, polystyrene, and polytetrafluoroethylene”,Biomaterials, vol. 21, No. 1., pp. 31-36, (2000).
Calias Pericles
Miller Robert J.
Genzyme Corporation
Naff David M.
LandOfFree
Biologically active conjugate of a biopolymer and... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Biologically active conjugate of a biopolymer and..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Biologically active conjugate of a biopolymer and... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4002925